ArticleRheumatology international2009
Lupus nephritis among 624 cases of systemic lupus erythematosus in Riyadh, Saudi Arabia.
Article in Rheumatology international, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Characteristics and Histological Types of Lupus Nephritis in a Jordanian Tertiary Medical Center.BioMed research international · 2019Trial
- Sex-based differences in clinical phenotype and damage accrual among patients with systemic lupus erythematosus in Saudi Arabia: a multicenter cross-sectional study.Clinical rheumatology · 2026Article
- Kidney Biopsy and Prognosis in Lupus Nephritis: Histological Predictors of Renal Outcome-A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Clinical outcomes and prognostic factors in lupus nephritis: impact of remission on renal and overall survival in a single-center study.BMC nephrology · 2026Article
- Article
- Clinical Presentation and Long-Term Outcomes of Lupus Nephritis in Palestine: A Multicenter Retrospective Study.Cureus · 2025Article
- Insight into prevalence, etiology, and modalities of pediatric chronic dialysis: a comprehensive nationwide analysis.Pediatric nephrology (Berlin, Germany) · 2024Article
- Review
- Molecular signatures of intrarenal complement receptorsLupus science & medicine · 2022Article
- Management practice and treatment outcomes of adult patients with Lupus Nephritis at the Renal Clinic of St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia.BMC nephrology · 2022Article
- Delayed Onset Minimal Change Disease as a Manifestation of Lupus Podocytopathy.Clinics and practice · 2021Article
- Treatment Outcomes of Proliferative vs. Non-proliferative Adult Lupus Nephritis: A 10-Year Follow-Up.Cureus · 2021Article
- Disease phenotype and diagnostic delay in Saudi patients with primary Sjögren's syndrome: An exploratory cross-sectional study.Saudi medical journal · 2021Article
- Launching the Saudi Arthritis Registry.Clinical rheumatology · 2021Article
- Lupus nephritis: clinical presentations and outcomes in the 21st century.Rheumatology (Oxford, England) · 2020Review
- Review
- Sex differences in clinical presentation of systemic lupus erythematosus.Biology of sex differences · 2019Article
- A Systematic Review and Meta-analysis of Prevalence of Biopsy-Proven Lupus Nephritis.Archives of rheumatology · 2018Article
- Glomerulonephritis disease pattern at Saudi tertiary care center.Saudi medical journal · 2017Article
- Mortality in Systemic Lupus Erythematosus: an Updated Review.Current rheumatology reports · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this article is to study the prevalence, clinicolaboratory features, WHO histological types, therapy and renal outcome of lupus nephritis (LN) in Saudi Arabia. During the 27-year-period (1980-2006), 299 (47.9%) cases of LN were identified among the 624 cases of systemic lupus erythematosus (SLE) follow-up at King Khalid University Hospital, Riyadh. The female:male ratio in LN was 8.3:1, with a mean age of 32 years and a mean age of onset of 23 years. The WHO renal histological types were; Class I (1%), Class II (18.1%), Class III (10%), Class IV (37.1%), Class V (11.7%), and Class VI (2.7%). Azathioprine was given to 43.1% and pulse cyclophosphamide to 65.6% in combination with other drugs. Remission was seen in 226 (75.6%) patients, renal flares in 14 (4.7%), end stage renal disease (ESRD) in 27 (9.0%), death in 18 (6.0%), and 14 (4.7%) lost follow-up. The 5- and 10-year patient survival rates in our whole LN cohort by Kaplan-Meier analysis were 96% and 95%, respectively. The survival did not differ significantly in different LN classes nor did it differ significantly during the three periods of presentation (1980-1990, 1991-2000, and 2001-2006; P > 0.05). The risk factors for poor survival were found to be older age at onset (>50-years age; P = 0.034), ESRD (P = 0.000), and low C3 (P = 0.022). The risk factors for progression to ESRD were older age at onset (>50-years age; P = 0.037), hypertension (P = 0.009), elevated serum creatinine (P = 0.000), and proliferative LN (Classes III, IV; P = 0.013, P = 0.039). Different treatment modalities did not have significant effect on survival in the whole LN cohort (P = >0.05). However, pulse cyclophosphamide favored remission in Classes II, III, IV, and V (P = 0.023). The main causes of death were renal failure (50%) and infections (44.4%).
Indexed as
Identifiers
19381639What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.